Vericel Corporation (FRA:ATQP)

Market Cap	1.49B -18.4%
Revenue (ttm)	235.29M +16.5%
Net Income	14.07M +59.4%
EPS	0.27 +60.0%
Shares Out	n/a
PE Ratio	106.18
Forward PE	79.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9
Open	29.40
Previous Close	29.00
Day's Range	29.40 - 29.40
52-Week Range	25.40 - 39.40
Beta	n/a
RSI	50.95
Earnings Date	May 7, 2026

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 398
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ATQP

Financial Performance

In 2025, Vericel's revenue was $276.26 million, an increase of 16.45% compared to the previous year's $237.22 million. Earnings were $16.52 million, an increase of 59.41%.

Financial numbers in USD